Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ampreloxetine in Hepatic Impairment
NCT04200573Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH) (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Plasma Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration, Plasma Area Under the Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Jan 2020; status: completed.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT04200573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200573.